Bristol Myers Squibb (BMY) Liabilities and Shareholders Equity (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $86.5 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $86.5 billion, down 6.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $368.1 billion (down 1.41% YoY), and the FY2025 annual result was $90.0 billion, down 2.77% from the prior year.
• Liabilities and Shareholders Equity fell to $86.5 billion in Q1 2026 per BMY's latest filing, from $90.0 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $103.0 billion in Q1 2022 and troughed at $86.5 billion in Q1 2026.
• A 5-year average of $94.9 billion and a median of $94.6 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity dropped 11.45% in 2022, then gained 5.04% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $96.8 billion in 2022, then declined by 1.72% to $95.2 billion in 2023, then declined by 2.69% to $92.6 billion in 2024, then dropped by 2.77% to $90.0 billion in 2025, then decreased by 3.96% to $86.5 billion in 2026.
• Business Quant data shows BMY's Liabilities and Shareholders Equity at $86.5 billion in Q1 2026, $90.0 billion in Q4 2025, and $96.9 billion in Q3 2025.